A recent study indicates that people who stop using blockbuster GLP-1 drugs like Mounjaro or Wegovy tend to recover lost weight much more quickly than those who halt conventional diet and exercise regimens.
Findings released in a leading medical journal demonstrates that while obese individuals frequently drop substantial amounts of their total mass while on the medication, the weight is regained at an average rate of nearly a kilo each month after stopping.
"People purchasing these treatments must be aware of the potential of quick rebound weight gain when the treatment is stopped," warns researcher Dr. Susan Jebb.
That rate of regain means a return to starting weight in about 18 months.
Analyzing Therapies
The research, which examined dozens of studies involving thousands of patients, contrasted the outcomes of these new drugs with conventional dieting.
The team note that individuals who shed pounds through diet and exercise typically experience a slower creep back—approximately 100 grams monthly—post-intervention.
Explaining the Quick Rebound
Doctors propose the mechanism of the drugs explains the accelerated weight return.
The injections copy a body's own chemical called glucagon-like peptide-1, which helps regulate appetite.
"Sustained high doses of the hormone levels several times higher than normal might result in the body to generate a reduced amount of its own natural hormone, and could diminish responsiveness to its actions," explained Dr. Adam Collins, a dietetics expert.
"Withdrawal of this medication leads to hunger is uncontrolled, making binge eating much more probable."
A Lifelong Disease?
The NHS recommend the injections for people with obesity-related health risks, alongside recommended lifestyle changes.
Many experts argue that, due to the high risk of weight regain, the therapy might need to be life-long.
This perspective is supported by pharmaceutical companies, who note that the results "emphasize the chronic character of excess weight," akin to managing conditions like diabetes.
User Accounts
Individuals who have stopped the jabs describe a intense return of cravings.
"It felt as if something flipping and I was suddenly starving," recalled a patient.
The struggle is worsened if patients have not established lasting lifestyle or habit changes during treatment.
Significant Interest
Survey data suggest that a significant number of adults in the UK have tried these injections in the past year, with desire continuing to grow.
- Adoption is higher among females compared to men.
- The 40s and 50s demographic shows the greatest level of interest.
- Many obtain the medications through private prescriptions rather than the NHS.
Finally, researchers stress that while GLP-1 drugs are powerful agents for weight loss, they are not a standalone fix and long-term success likely depends on combined behavioural support.
